Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FlexPro MD (FP-MD) is a multi-ingredient dietary supplement formulated for joint health, specifically targeting joint pain and inflammation associated with mild osteoarthritis of the knee or hip. The formulation contains a proprietary blend of Antarctic krill oil (*Euphausia superba*), which provides phospholipid-bound omega-3 polyunsaturated fatty acids; natural astaxanthin derived from *Haematococcus pluvialis* algae; and low molecular weight hyaluronic acid produced through fermentation by *Streptococcus zooepidemicus*. The supplement exerts its therapeutic effect by inhibiting the NF-κB inflammatory signaling pathway, thereby reducing joint inflammation. Clinical trials have demonstrated that daily supplementation over 12 weeks significantly reduces joint pain and improves physical function in patients with osteoarthritis. It was developed by Valensa International, with clinical funding and encapsulation provided by NOVAREX.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on FlexPro MD.